Literature DB >> 27210746

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Zsolt Sebestyen1, Wouter Scheper1, Anna Vyborova1, Siyi Gu2, Zuzana Rychnavska1, Marleen Schiffler1, Astrid Cleven1, Coraline Chéneau1, Martje van Noorden1, Cassie-Marie Peigné3, Daniel Olive4, Robert Jan Lebbink5, Rimke Oostvogels2, Tuna Mutis2, Gerrit Jan Schuurhuis6, Erin J Adams7, Emmanuel Scotet3, Jürgen Kuball8.   

Abstract

Human Vγ9Vδ2 T cells respond to tumor cells by sensing elevated levels of phosphorylated intermediates of the dysregulated mevalonate pathway, which is translated into activating signals by the ubiquitously expressed butyrophilin A1 (BTN3A1) through yet unknown mechanisms. Here, we developed an unbiased, genome-wide screening method that identified RhoB as a critical mediator of Vγ9Vδ2 TCR activation in tumor cells. Our results show that Vγ9Vδ2 TCR activation is modulated by the GTPase activity of RhoB and its redistribution to BTN3A1. This is associated with cytoskeletal changes that directly stabilize BTN3A1 in the membrane, and the subsequent dissociation of RhoB from BTN3A1. Furthermore, phosphoantigen accumulation induces a conformational change in BTN3A1, rendering its extracellular domains recognizable by Vγ9Vδ2 TCRs. These complementary events provide further evidence for inside-out signaling as an essential step in the recognition of tumor cells by a Vγ9Vδ2 TCR.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27210746      PMCID: PMC5035041          DOI: 10.1016/j.celrep.2016.04.081

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  52 in total

Review 1.  Clostridium botulinum C3 ADP-ribosyltransferase.

Authors:  K Aktories; C Mohr; G Koch
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap.

Authors:  Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker
Journal:  Bioinformatics       Date:  2008-10-30       Impact factor: 6.937

3.  Centre d'etude du polymorphisme humain (CEPH): collaborative genetic mapping of the human genome.

Authors:  J Dausset; H Cann; D Cohen; M Lathrop; J M Lalouel; R White
Journal:  Genomics       Date:  1990-03       Impact factor: 5.736

4.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

5.  Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6.

Authors:  Felipe Riaño; Mohindar M Karunakaran; Lisa Starick; Jianqiang Li; Claus J Scholz; Volker Kunzmann; Daniel Olive; Sabine Amslinger; Thomas Herrmann
Journal:  Eur J Immunol       Date:  2014-06-30       Impact factor: 5.532

6.  Actin restricts FcepsilonRI diffusion and facilitates antigen-induced receptor immobilization.

Authors:  Nicholas L Andrews; Keith A Lidke; Janet R Pfeiffer; Alan R Burns; Bridget S Wilson; Janet M Oliver; Diane S Lidke
Journal:  Nat Cell Biol       Date:  2008-07-20       Impact factor: 28.824

Review 7.  Exploring the diversity of SPRY/B30.2-mediated interactions.

Authors:  Livia Perfetto; Pier Federico Gherardini; Norman E Davey; Francesca Diella; Manuela Helmer-Citterich; Gianni Cesareni
Journal:  Trends Biochem Sci       Date:  2012-11-17       Impact factor: 13.807

8.  A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation.

Authors:  Michael L van de Weijer; Michael C Bassik; Rutger D Luteijn; Cornelia M Voorburg; Mirjam A M Lohuis; Elisabeth Kremmer; Rob C Hoeben; Emily M LeProust; Siyuan Chen; Hanneke Hoelen; Maaike E Ressing; Weronika Patena; Jonathan S Weissman; Michael T McManus; Emmanuel J H J Wiertz; Robert Jan Lebbink
Journal:  Nat Commun       Date:  2014-05-08       Impact factor: 14.919

9.  Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Authors:  Monique Terwijn; Wendelien Zeijlemaker; Angèle Kelder; Arjo P Rutten; Alexander N Snel; Willemijn J Scholten; Thomas Pabst; Gregor Verhoef; Bob Löwenberg; Sonja Zweegman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

10.  Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors.

Authors:  Daniel V Correia; António Lopes; Bruno Silva-Santos
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more
  56 in total

1.  Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

Authors:  Maria Raffaella Zocchi; Delfina Costa; Roberta Venè; Francesca Tosetti; Nicoletta Ferrari; Simona Minghelli; Roberto Benelli; Stefano Scabini; Emanuele Romairone; Silvia Catellani; Aldo Profumo; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  Critical Roles for Coiled-Coil Dimers of Butyrophilin 3A1 in the Sensing of Prenyl Pyrophosphates by Human Vγ2Vδ2 T Cells.

Authors:  Hong Wang; Mohanad H Nada; Yoshimasa Tanaka; Shun Sakuraba; Craig T Morita
Journal:  J Immunol       Date:  2019-06-21       Impact factor: 5.422

3.  The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.

Authors:  Khiem Nguyen; Jin Li; Robbins Puthenveetil; Xiaochen Lin; Michael M Poe; Chia-Hung Christine Hsiao; Olga Vinogradova; Andrew J Wiemer
Journal:  FASEB J       Date:  2017-07-13       Impact factor: 5.191

Review 4.  Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge.

Authors:  Daniel G Pellicci; Hui-Fern Koay; Stuart P Berzins
Journal:  Nat Rev Immunol       Date:  2020-06-24       Impact factor: 53.106

5.  Nature Biotechnology's academic spinouts of 2016.

Authors:  Aaron Bouchie; Laura DeFrancesco; Cormac Sheridan; Sarah Webb
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

6.  Vγ9Vδ2 T cell activation by strongly agonistic nucleotidic phosphoantigens.

Authors:  Morgane Moulin; Javier Alguacil; Siyi Gu; Asmaa Mehtougui; Erin J Adams; Suzanne Peyrottes; Eric Champagne
Journal:  Cell Mol Life Sci       Date:  2017-07-01       Impact factor: 9.261

7.  Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.

Authors:  Siyi Gu; Joseph R Sachleben; Christopher T Boughter; Wioletta I Nawrocka; Marta T Borowska; Jeffrey T Tarrasch; Georgios Skiniotis; Benoît Roux; Erin J Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

8.  TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice.

Authors:  Inez Johanna; Patricia Hernández-López; Sabine Heijhuurs; Laura Bongiovanni; Alain de Bruin; Dennis Beringer; Sanne van Dooremalen; Leonard D Shultz; Fumihiko Ishikawa; Zsolt Sebestyen; Trudy Straetemans; Jürgen Kuball
Journal:  J Leukoc Biol       Date:  2020-02-05       Impact factor: 4.962

9.  Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism.

Authors:  Rebekah R Shippy; Xiaochen Lin; Sherry S Agabiti; Jin Li; Brendan M Zangari; Benjamin J Foust; Michael M Poe; Chia-Hung Christine Hsiao; Olga Vinogradova; David F Wiemer; Andrew J Wiemer
Journal:  J Med Chem       Date:  2017-03-01       Impact factor: 7.446

10.  A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

Authors:  Renée C G de Bruin; John P Veluchamy; Sinéad M Lougheed; Famke L Schneiders; Silvia Lopez-Lastra; Roeland Lameris; Anita G Stam; Zsolt Sebestyen; Jürgen Kuball; Carla F M Molthoff; Erik Hooijberg; Rob C Roovers; James P Di Santo; Paul M P van Bergen En Henegouwen; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Oncoimmunology       Date:  2017-10-20       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.